Amarin investors know by now that the big news for the company will be whether its drug Vascepa gets new chemical entity, or NCE, status from the FDA, and so far, the wait has been long for an answer. In the meantime, the company is taking other measures to protect its drug from generic competition. Vascepa was just granted its ninth U.S. patent, and Amarin plans to apply for a 10th. In this video, Motley Fool analysts Max Macaluso and David Williamson discuss another factor that can give the company competitive leverage: increasing the number of suppliers it gets Vascepa's active ingredient from.
The biotech space can make or break investors overnight, and while Amarin certainly won't go under if Vascepa doesn't get NCE status, the success of this new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with Max's premium research report. Click here now to keep reading.